Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 15;22(12):6385.
doi: 10.3390/ijms22126385.

Molecular Mechanisms of Drug Resistance in Glioblastoma

Maya A Dymova  1 , Elena V Kuligina  1 , Vladimir A Richter  1
Affiliations
Review

Molecular Mechanisms of Drug Resistance in Glioblastoma

Maya A Dymova et al. Int J Mol Sci. .

Abstract

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB).

Keywords: drug resistance; glioblastoma multiforme; molecular mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main issues related to the development of drug resistance in glioblastoma multiforme (GBM).
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590. - DOI - PubMed
    1. Tamimi A.F., Juweid M. Epidemiology and Outcome of Glioblastoma Incidence of Glioblastoma. In: De Vleeschouwer S., editor. Glioblastoma. Codon Publications; Brisbane, Australia: 2017. p. 14. - PubMed
    1. Nuzzo S., Brancato V., Affinito A., Salvatore M., Cavaliere C., Condorelli G. The role of RNA and DNA aptamers in glioblastoma diagnosis and therapy: A systematic review of the literature. Cancers. 2020;12:2173. doi: 10.3390/cancers12082173. - DOI - PMC - PubMed
    1. Davis M.E. Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 2016;20:S2–S8. doi: 10.1188/16.CJON.S1.2-8. - DOI - PMC - PubMed
    1. Seystahl K., Network T.G.G., Hentschel B., Loew S., Gramatzki D., Felsberg J., Herrlinger U., Westphal M., Schackert G., Thon N., et al. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. J. Cancer Res. Clin. Oncol. 2019;146:659–670. doi: 10.1007/s00432-019-03086-9. - DOI - PMC - PubMed